Imaging of genetic aspects of parkinson's disease;Neurobildgebung genetischer aspekte der parkinson-krankheit

Nervenarzt

Volumn 81, Issue 10, 2010, Pages 1196-1203

  Bruggemann N ^a,b   Vegt, J ^b,c   Klein, C ^a   Siebner, H R ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Magnetic resonance imaging; Neurogenetics; Parkinson disease; Positron emission tomography; Voxel based morphometry

Indexed keywords

GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; VOXEL BASED MORPHOMETRY;

BRAIN; DNA MUTATIONAL ANALYSIS; DOPAMINE; EARLY DIAGNOSIS; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RECEPTORS, DOPAMINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78650416324     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-010-3024-6     Document Type: Review

References (54)

1. Adams JR, Netten H van, Schulzer M et al (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128:2777-2785
2. Ahn TB, Kim SY, Kim JY et al (2008) alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70:43-49
3. Albanese A, Valente EM, Romito LM et al (2005) The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64:1958-1960
4. Ashburner J, Friston KJ (2000) Voxel-based morphometry - the methods. Neuroimage 11:805-821
5. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044-1055
6. Berg D, Roggendorf W, Schroder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-1005
7. Binkofski F, Reetz K, Gaser C et al (2007) Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 69:842-850
8. Bonifati V, Rizzu P, Baren MJ van et al (2003) Mutations in the DJ-1 gene associated with autosomal-recessive early-onset parkinsonism. Science 299:256-259
9. Brooks DJ (2004) Neuroimaging in Parkinson's disease. NeuroRx 1:243-254
10. Brueggemann N, Odin P, Gruenewald A et al (2008) Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 71:1294 (author reply 1294)
11. Buhmann C, Binkofski F, Klein C et al (2005) Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 128:2281-2290
12. Lau LM de, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525-535
13. Rijk MC de, Launer LJ, Berger K et al (2000) Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54: S21-S23
14. Dekker MC, Eshuis SA, Maguire RP et al (2004) PET neuroimaging and mutations in the DJ-1 gene. J Neural Transm 111:1575-1581
15. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636-645
16. Hagenah JM, Becker B, Bruggemann N et al (2008) Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 79:1071-1074
17. Hagenah JM, Konig IR, Becker B et al (2007) Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 254:1407-1413
18. Hedrich K, Hagenah J, Djarmati A et al (2006) Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 63:833-838
19. Hering R, Strauss KM, Tao X et al (2004) Novel homozygous p. E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 24:321-329
20. Hilker R, Klein C, Ghaemi M et al (2001) Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 49:367-376
21. Hu MT, Scherfler C, Khan NL et al (2006) Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. Mov Disord 21:299-305
22. Isaias IU, Benti R, Goldwurm S et al (2006) Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Mov Disord 21:1144-1147
23. Kessler KR, Hamscho N, Morales B et al (2005) Dopaminergic function in a family with the PARK6 form of autosomal-recessive Parkinson's syndrome. J Neural Transm 112:1345-1353
24. Khan NL, Brooks DJ, Pavese N et al (2002) Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125:2248-2256
25. Khan NL, Jain S, Lynch JM et al (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796
26. Khan NL, Valente EM, Bentivoglio AR et al (2002) Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 52:849-853
27. Kitada T, Asakawa S, Hattori N et al (1998) Mutations in the parkin gene cause autosomal-recessive juvenile parkinsonism. Nature 392:605-608
28. Kruger R, Kuhn W, Leenders KL et al (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56:1355-1362
29. Lang AE, Obeso JA (2004) Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 3:309-316
30. Lee CS, Samii A, Sossi V et al (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47:493-503
31. Logothetis NK (2008) What we can do and what we cannot do with fMRI. Nature 453:869-878
32. Nandhagopal R, McKeown MJ, Stoessl AJ (2008) Functional imaging in Parkinson disease. Neurology 70:1478-1488
33. Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600
34. Pellecchia MT, Varrone A, Annesi G et al (2007) Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. Mov Disord 22:559-563
35. Piccini P (2004) Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol 17:459-466
36. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
37. Reetz K, Gaser C, Klein C et al (2009) Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov Disord 24:99-103
38. Reetz K, Lencer R, Steinlechner S et al (2008) Limbic and frontal cortical degeneration is associated with psychiatric symptoms in PINK1 mutation carriers. Biol Psychiatry 64:241-247
39. Reetz K, Siebner HR, Gaser C et al (2008) Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease. Open Neuroimag J 2:102-105
40. Reetz K, Tadic V, Kasten M et al (2010) Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 39:402-408
41. Samii A, Markopoulou K, Wszolek ZK et al (1999) PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 53:2097-2102
42. Scherfler C, Khan NL, Pavese N et al (2004) Striatal and cortical pre-and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127:1332-1342
43. Scherfler C, Khan NL, Pavese N et al (2006) Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord 21:783-788
44. Shih MC, Amaro E Jr, Ferraz HB et al (2006) Neuroimaging of the dopamine transporter in Parkinsons disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil. Arq Neuropsiquiatr 64:628-634
45. Siebner HR, Callicott JH, Sommer T, Mattay VS (2009) From the genome to the phenome and back: linking genes with human brain function and structure using genetically informed neuroimaging. Neuroscience 164:1-6
46. Steinlechner S, Stahlberg J, Voelkel B et al (2007) Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry 78:532-535
47. Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160
48. Vegt JP van der, Nuenen BF van, Bloem BR et al (2009) Imaging the impact of genes on Parkinson's disease. Neuroscience 164:191-204
49. Eimeren T van, Binkofski F, Buhmann C et al (2010) Imaging movement-related activity in medicated Parkin-associated and sporadic Parkinson's disease. Parkinsonism Relat Disord 16:384-387
50. Eimeren T van, Siebner HR (2006) An update on functional neuroimaging of parkinsonism and dystonia. Curr Opin Neurol 19:412-419
51. Nuenen BF van, Weiss MM, Bloem BR et al (2009) Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 72:1041-1047
52. Varrone A, Pellecchia MT, Amboni M et al (2004) Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology 63:2097-2103
53. Verstappen CC, Bloem BR, Haaxma CA et al (2007) Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 34:502-507
54. Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607